Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 9MW2821 versus investigator's choice chemotherapy in platinum-failed recurrent or metastatic cervical cancer
CTR20243246Phase 3Active
- Sponsor
- Mabwell
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bulumtatug fuvedotin in Cervical Cancer (CC), sponsored by Mabwell. Started Sep 2024; status: active.
02
Drugs
bulumtatug fuvedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20243246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243246.